AMIDEBIO
AmideBio, LLC, a biotechnology company, focuses on the development, production, and commercialization of peptide research reagents and clinical products for research and development, clinical, and therapeutic marketplaces.
AMIDEBIO
Industry:
Biotechnology Health Care Therapeutics
Founded:
2009-01-01
Address:
Louisville, Colorado, United States
Country:
United States
Website Url:
http://www.AmideBio.com
Total Employee:
1+
Status:
Active
Contact:
303 604 0296
Total Funding:
2.59 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Sitelinks Search Box
Current Advisors List
Board_member
2001-04-01
Current Employees Featured
Michael H. B Stowell Founder & CTO @ AmideBio
Founder & CTO
Mikhail Misha Plam President & CEO @ AmideBio
President & CEO
2009-01-01
Founder
Official Site Inspections
http://www.AmideBio.com
- Host name: 143.198.146.38
- IP address: 143.198.146.38
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AmideBio"
Home | Amidebio | Novel Peptides Targeting Metabolic …
AmideBio is leveraging its in-silico design and proprietary peptide synthesis capabilities to develop a pipeline of unique peptide drug candidates targeting some of the biggest therapeutic challenges for metabolic disease. In addition, …See details»
AmideBio - Crunchbase Company Profile & Funding
AmideBio, LLC, a biotechnology company, focuses on the development, production, and commercialization of peptide research reagents and clinical products for research and …See details»
About | Amidebio | Novel Peptides Targeting Metabolic Disease
AmideBio was founded in 2009 to commercialize the proprietary BioPure platform technology to deliver difficult-to-manufacture, ultrapure peptides to the biopharmaceutical industry and …See details»
amidebio.com Reviews: Is this site a scam or legit?
Organization Proxy Protection LLC . Owner Proxy Protection LLC . Address 417 Associated Rd #327 C/O amidebio.com . State CA . Country UNITED STATES . Country Code US . ...See details»
AmideBio 2025 Company Profile: Valuation, Funding & Investors
AmideBio General Information Description. Operator of a biotechnology company intended to develop peptide therapeutics for metabolic disease The company's platform develops and …See details»
AmideBio, LLC Company Profile | Louisville, CO | Competitors ...
Find company research, competitor information, contact details & financial data for AmideBio, LLC of Louisville, CO. Get the latest business insights from Dun & Bradstreet.See details»
AmideBio - Org Chart, Teams, Culture & Jobs - The Org
View AmideBio's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
AmideBio - Funding, Financials, Valuation & Investors - Crunchbase
Organization. AmideBio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 8. obfuscated. ... AmideBio …See details»
AmideBio Company Profile - Office Locations, Competitors ... - Craft
AmideBio has 5 employees across 2 locations and $2.59 m in total funding,. See insights on AmideBio including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
AmideBio - 2025 Company Profile, Funding & Competitors - Tracxn
Mar 20, 2025 AmideBio is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. It …See details»
AmideBio - Contacts, Employees, Board Members, Advisors
AmideBio develops and commercializes peptide research reagents and clinical products for clinical and therapeutic marketplaces. ... Experience the new Crunchbase, powered by AI . …See details»
AmideBio - Products, Competitors, Financials, Employees, …
About AmideBio. AmideBio focuses on the development of novel peptides for the treatment of metabolic diseases within the biotechnology sector. The company leverages in-silico design …See details»
AmideBio - Overview, News & Similar companies | ZoomInfo.com
Aug 20, 2020 AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development …See details»
AmideBio, LLC | Venture Partners at CU Boulder - University of …
AmideBio discovers and develops novel peptides for the treatment of metabolic diseases. In addition, AmideBio leverages its proprietary BioPure™ peptide manufacturing technology to …See details»
AmideBio - Tech Stack, Apps, Patents & Trademarks - Crunchbase
AmideBio develops and commercializes peptide research reagents and clinical products for clinical and therapeutic marketplaces. New. Resources. Advanced Search. Start Free Trial . …See details»
Novel Peptides Targeting Metabolic Disease - Amidebio
AmideBio has built a catalog of peptides using its BioPure process ensuring unequaled purity and lack of contaminating side and by-products. While other manufacturers strive to achieve 97% …See details»
Boulder’s AmideBio wins SBIR grant for diabetes treatment research
Sep 16, 2024 Small Business Innovation Research grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) “will allow AmideBio to develop a dual …See details»
News | Amidebio | Novel Peptides Targeting Metabolic Disease
Sep 3, 2018 BOULDER, CO, March 8, 2021 – AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received $300,000 in funding …See details»
If Anthropic Succeeds, a Nation of Benevolent AI Geniuses Could …
Mar 28, 2025 The brother goes on vision quests. The sister is a former English major. Together, they defected from OpenAI, started Anthropic, and built (they say) AI’s most upstanding …See details»
AmideBio Awarded SBIR Phase IIB Grant to Support Pre-Clinical ...
BOULDER, CO, October 4th, 2022 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $2.69M in funding through a Phase IIB Small …See details»